Residency · Residency · Urology

Acute and Chronic Prostatitis

Introduction

Prostatitis syndromes represent a diverse group of conditions affecting the prostate gland, ranging from acute bacterial infections that may require hospitalization to chronic pelvic pain syndromes, which are among the most challenging conditions in urology. The National Institutes of Health (NIH) classification system categorizes prostatitis into four distinct groups, each characterized by unique pathophysiology, diagnostic approaches, and treatment strategies. Prostatitis is a common clinical problem, accounting for approximately 2 million outpatient visits annually in the United States and affecting up to 15% of men at some point in their lives.

NIH Classification of Prostatitis

The NIH classification divides prostatitis into four categories. Category I is acute bacterial prostatitis, characterized by sudden onset infection. Category II is chronic bacterial prostatitis, involving persistent bacterial infection. Category III encompasses chronic prostatitis or chronic pelvic pain syndrome (CP/CPPS), which is further subdivided into IIIa, the inflammatory type with leukocytes present in expressed prostatic secretions, and IIIb, the non-inflammatory type without leukocytes. Finally, Category IV is asymptomatic inflammatory prostatitis, identified histologically without symptoms.

Category I: Acute Bacterial Prostatitis

Pathophysiology

The most common mechanism for acute bacterial prostatitis is an ascending urethral infection, where bacteria travel up the urethra to infect the prostate. Additionally, intraprostatic reflux of infected urine into the prostatic ducts can contribute to infection. Although rare, hematogenous spread of bacteria to the prostate is also possible. Risk factors for acute bacterial prostatitis include recent urologic instrumentation, the presence of an indwelling catheter, unprotected anal intercourse, and phimosis.

Microbiology

Escherichia coli is the predominant pathogen, responsible for 50-80% of cases. Other gram-negative bacteria such as Klebsiella, Proteus, Pseudomonas, and Enterobacter species are also implicated. Enterococcus species are more commonly seen in cases following instrumentation. In sexually active young men, Neisseria gonorrhoeae and Chlamydia trachomatis should be considered as potential causative agents.

Clinical Presentation

Patients typically present with an acute onset of fever, chills, malaise, and pain localized to the perineum or lower back. Irritative voiding symptoms such as dysuria, frequency, and urgency are common, along with obstructive symptoms including hesitancy, weak urinary stream, and in about 10% of cases, acute urinary retention. On digital rectal examination, the prostate is tender, boggy, and warm; however, vigorous prostatic massage is contraindicated due to the risk of inducing bacteremia.

<image>Anatomical cross-section of the male pelvis showing an acutely inflamed and edematous prostate gland with surrounding inflammation, highlighting the relationship to the urethra, bladder neck, and rectum</image>

Diagnosis

Diagnosis relies on urinalysis and urine culture, which typically reveal pyuria and bacteriuria. Blood cultures should be obtained in all febrile patients, with positivity in 20-30% of cases. Prostate-specific antigen (PSA) levels are often elevated during acute infection but should not be measured at this time due to lack of specificity. Transrectal ultrasound is reserved for cases where a prostatic abscess is suspected, particularly if there is no clinical improvement after 48-72 hours of appropriate antibiotic therapy.

Management

Mild cases of acute bacterial prostatitis can be treated with oral fluoroquinolones such as ciprofloxacin 500 mg twice daily or levofloxacin 500 mg daily for 4-6 weeks. Severe cases or those complicated by sepsis require intravenous antibiotics, including combinations such as ampicillin plus gentamicin, IV fluoroquinolones, or IV ceftriaxone, with a transition to oral therapy once the patient is afebrile. In cases of acute urinary retention, suprapubic catheterization is preferred over urethral catheterization to avoid compressing the inflamed prostate. If a prostatic abscess larger than 2 cm develops, incision and drainage via transurethral resection or transrectal/transperineal aspiration is indicated.

Category II: Chronic Bacterial Prostatitis

Pathophysiology

Chronic bacterial prostatitis results from persistent bacterial infection within the prostate despite initial treatment. Prostatic calculi often serve as a nidus for bacterial biofilm formation, allowing bacteria to evade eradication. The persistence of bacteria within the prostatic acini is facilitated by poor antibiotic penetration and the alkaline nature of prostatic fluid, which can reduce antibiotic efficacy.

Clinical Presentation

Patients typically experience recurrent urinary tract infections caused by the same organism. Symptoms include intermittent pelvic pain, dysuria, and discomfort during ejaculation. These symptoms tend to wax and wane over months to years, making diagnosis challenging.

Diagnosis: The Meares-Stamey Four-Glass Test

Diagnosis involves the Meares-Stamey four-glass test, which sequentially collects specimens to localize infection. VB1 is the first-void urine representing urethral flora, VB2 is midstream urine reflecting bladder urine, EPS is expressed prostatic secretions obtained after prostatic massage, and VB3 is post-massage urine. A diagnosis of chronic bacterial prostatitis is made when the bacterial count in EPS or VB3 is at least ten times greater than in VB1 and VB2. A simplified alternative is the pre- and post-massage test (PPMT), which compares bacterial counts in urine collected before and after prostatic massage.

<image>Diagram of the Meares-Stamey four-glass test showing sequential urine collection steps (VB1, VB2, EPS, VB3) with labeled collection containers and expected findings in chronic bacterial prostatitis</image>

Management

First-line treatment consists of fluoroquinolones such as ciprofloxacin or levofloxacin for 4-6 weeks due to their excellent prostatic penetration. Trimethoprim-sulfamethoxazole is an alternative, typically administered for 6-12 weeks. Alpha-blockers like tamsulosin or alfuzosin may help alleviate symptoms and reduce recurrence rates. Surgical intervention, such as transurethral resection of the prostate (TURP), is reserved for refractory cases, especially when prostatic calculi are present.

Category III: Chronic Prostatitis / Chronic Pelvic Pain Syndrome

Epidemiology and Pathophysiology

Chronic prostatitis or chronic pelvic pain syndrome (CP/CPPS) is the most common form of prostatitis, accounting for 90-95% of cases. Its etiology is multifactorial and not well understood. Proposed mechanisms include neurogenic inflammation and central sensitization, pelvic floor myofascial dysfunction, autoimmune or inflammatory responses to prostatic antigens, and psychosocial factors such as anxiety, depression, and catastrophizing. The UPOINT phenotyping system categorizes CP/CPPS into six domains: Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, and Tenderness (pelvic floor), which helps guide individualized treatment.

Clinical Presentation

Patients with CP/CPPS experience chronic pelvic pain localized to the perineum, suprapubic region, penis, or testicles lasting three months or longer. Voiding dysfunction is common, including frequency, urgency, and weak stream. Sexual dysfunction such as painful ejaculation and erectile dysfunction may also occur. The condition significantly impairs quality of life, with an impact comparable to chronic illnesses like Crohn disease or heart failure.

Diagnosis

CP/CPPS is primarily a diagnosis of exclusion. It is important to rule out urinary tract infection, urethral stricture, bladder cancer, and neurologic diseases. The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) is a validated questionnaire used to assess symptom severity and monitor treatment response. Baseline evaluation includes urinalysis, urine culture, and uroflowmetry. Cystoscopy and urodynamic studies are reserved for atypical cases.

Multimodal Management

Management of CP/CPPS requires a multimodal approach tailored to the patient's phenotype. Alpha-blockers such as tamsulosin 0.4 mg daily for 6-12 weeks are most effective in treatment-naive patients. Phytotherapy agents including quercetin, saw palmetto, and pollen extract (Cernilton) have modest evidence supporting their use. Pelvic floor physical therapy is a cornerstone of treatment for patients with pelvic floor tenderness. Neuromodulatory agents like amitriptyline, gabapentin, and pregabalin may be used to address neuropathic pain components. Cognitive behavioral therapy can help manage psychosocial factors and catastrophizing. Empiric antibiotic therapy should only be attempted if not previously tried and discontinued if no improvement occurs within 4-6 weeks. Repeated antibiotic courses without culture evidence and invasive prostatic procedures should be avoided.

<image>Illustration of the UPOINT clinical phenotyping system for CP/CPPS, showing six domains (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/Systemic, Tenderness) arranged in a circular diagram with associated treatment strategies for each domain</image>

Category IV: Asymptomatic Inflammatory Prostatitis

Asymptomatic inflammatory prostatitis is typically an incidental finding on prostate biopsy, semen analysis, or examination of prostatic tissue specimens. It does not require treatment unless the patient is undergoing fertility evaluation, as inflammation may impair semen parameters. This condition may also contribute to elevated PSA levels, which can lead to unnecessary prostate biopsies.

Key Clinical Pearls

In suspected acute bacterial prostatitis, vigorous prostatic massage should never be performed due to the risk of bacteremia and sepsis. For urinary retention in acute prostatitis, suprapubic catheterization is preferred over urethral catheterization to avoid compressing the inflamed prostate. Chronic prostatitis/chronic pelvic pain syndrome requires a multimodal, phenotype-directed treatment approach rather than repeated empiric antibiotic courses. The UPOINT system is valuable for individualizing therapy and improving outcomes. Fluoroquinolones remain the first-line antibiotics for bacterial prostatitis because of their superior lipid solubility and excellent penetration into prostatic tissue.

References

1. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236-237.
2. Nickel JC, Shoskes DA, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013;31(4):747-753.
3. Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73(3):538-542.
4. Wagenlehner FM, Pilatz A, Bschleipfer T, et al. Bacterial prostatitis. World J Urol. 2013;31(4):711-716.

Read this lecture as Markdown